التفاصيل البيبلوغرافية
| العنوان: |
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. |
| المؤلفون: |
De Stefano, Nicola, Comi, Giancarlo, Kappos, Ludwig, Freedman, Mark S., Polman, Chris H., Uitdehaag, Bernard M. J., Hennessy, Brian, Casset-Semanaz, Florence, Lehr, Lorenz, Stubinski, Bettina, Jack, Dominic L., Barkhof, Frederik |
| المصدر: |
Journal of Neurology, Neurosurgery & Psychiatry; Jun2014, Vol. 85 Issue 6, p647-653, 7p |
| مصطلحات موضوعية: |
INTERFERONS, MAGNETIC resonance imaging of the brain, CLINICAL drug trials, BRAIN disease treatment, NEUROLOGY |
| مستخلص: |
Aim The REbif FLEXible dosing in early MS (REFLEX) study compared several brain MRI outcomes in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis and treated with two dosefrequencies of subcutaneous interferon (IFN) ß-1a or placebo. Methods Patients were randomised (1:1:1) to IFN ß-1a, 44 mg subcutaneously three times a week or once a week, or placebo three times a week for up to 24 months. MRI scans were performed every 3 months, or every 6 months if the patient developed clinically definite multiple sclerosis. End points analysed included: number of combined unique active lesions per patient per scan; numbers and volumes of new T2, T1 hypointense and gadolinium-enhancing (Gd+) lesions per patient per scan; and brain volume. Results 517 patients were randomised (intent-to-treat population: subcutaneous IFN ß-1a three times a week, n=171; subcutaneous IFN ß-1a once a week, n=175; placebo, n=171). Combined unique active lesions were lower in patients treated with subcutaneous IFN ß-1a versus placebo (mean (SD) lesions per patient per scan: three times a week 0.6 (1.15); once a week 1.23 (4.26); placebo 2.70 (5.23); reduction versus placebo: three times a week 81%; once a week 63%; p<0.001) and with three times a week versus once a week (48% reduction; p=0.002). The mean numbers of new T2, T1 hypointense and Gd+ lesions were all significantly lower in the two active treatment arms compared with placebo (p≤0.004 for three times a week or once a week) and in the three times a week group compared with once a week (p≤0.012). Conclusions Both subcutaneous IFN ß-1a 44 mg regimens improved MRI outcomes versus placebo, with the three times a week regimen having a more pronounced effect than once a week dosing. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Neurology, Neurosurgery & Psychiatry is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder